[VIRTUAL] Five-year outcomes with adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage IIIB–C or IV melanoma (CheckMate 238)

[VIRTUAL] Neoadjuvant Canerpaturev (C-REV) Oncolytic Immunotherapy in Combination with Nivolumab (Nivo) in Resectable Advanced Melanoma

[VIRTUAL] Pembrolizumab (Pembro) Versus Placebo (PBO) After Complete Resection of High-Risk Stage II Melanoma: Updated Results From KEYNOTE-716

[VIRTUAL] Final results of the BAMM Trial: BRAF, Autophagy and MEK inhibition in Metastatic Melanoma: A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAF mutant melanoma

[VIRTUAL] The genomic and immune landscape of lethal uveal melanoma – a post-mortem study

[VIRTUAL] Phase 2 study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, plus pembrolizumab in patients (pts) with mucosal melanoma (MM) or uveal melanoma (UM) failing immuno-oncologic (I-O) drugs

[VIRTUAL] 7-year Follow-up of KEYNOTE-006: Pembrolizumab (pembro) Versus Ipilimumab (ipi) in Advanced Melanoma

[VIRTUAL] Preliminary results from the skin cancer cohorts from an ongoing multi-cohort phase 2 clinical trial of RP1 combined with nivolumab (IGNYTE)

[VIRTUAL] Randomized trial of precision prevention materials to improve skin cancer prevention activities among Hispanics

[VIRTUAL] Combining Fecal Microbiota Transplantation with Immunotherapy in Treatment-Naive Patients with Advanced Melanoma